In its third-quarter results update, Sanofi said the consumer health unit – which owns brands ... The range of consumer healthcare products it offers will also be “streamlined” ahead of ...

Sanofi is to take on Boehringer Ingelheim's consumer health division in exchange for ... a good fit with its existing business in terms of products and geographies, giving it much increased ...

French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which ...

After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business ... for switching drugs from prescription to OTC products and are meant to prove that consumers can adequately ...

The sale of Sanofi's controlling stake in consumer health business Opella is expected to close in the second quarter at the earliest, completing its transition into a pure-play drug and vaccine ...

The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility in Massachusetts.

Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Risinger from ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, maintained the Buy rating on Sanofi (SNYNF – Research Report). The associated price target ...

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ($916m) compared to a loss of €119m ($123.9m) in the same period ...

Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services ... backed by its innovation efforts. Sanofi’s new products like novel recombinant factor VIII therapy, Altuviiio ...